• Latest Posts

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

BiVictriX announces positive data from leukemia study

Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer

Hummingbird Bioscience and Synaffix to develop ADC program

Mersana Therapeutics and Merck to develop novel ADCs

Merck and Kelun-Biotech collaborating on seven ADC cancer candidates 


Watch: Araris Biotech at Bio-Europe

Solve Therapeutics launches to tackle cancer

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

More News! 8 Dec 2022

Enhertu’s positive results demonstrate improvement in overall survival

BiVictriX identifies development lead for ADC cancer program

SOTIO exercises option on ADC program